GeneDx Holdings Corp.
WGSNASDAQHealthcare● Active
$55.38
+$3.58(+6.91%)
Market Cap$1.6B
P/E Ratio—
52W High$170.87
52W Low$32.21
GeneDx Holdings Corp. (WGS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
WGS · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
-$0.28
Est. -$0.06 · -366.7%
Revenue
$0.10B
Est. $0.11B · -9.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
WGS reports quarterly as a NASDAQ-listed Medical - Healthcare Information Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.19 | — | — | — | $0.11B | — |
| ▼ Q2 FY2026 | May 4, 2026 | -$0.06 | -$0.28 | -366.7% | $0.10B | $0.11B | -9.1% |
| ▲ Q1 FY2026 | Feb 23, 2026 | $0.11 | $0.14 | +27.3% | $0.12B | $0.12B | +0.6% |
| ▲ Q4 FY2025 | Oct 28, 2025 | $0.28 | $0.49 | +75.0% | $0.12B | $0.12B | -3.1% |
| ▲ Q3 FY2025 | Jul 29, 2025 | $0.10 | $0.50 | +400.0% | $0.10B | $0.10B | +4.1% |
| ▲ Q2 FY2025 | Apr 30, 2025 | $0.11 | $0.28 | +154.6% | $0.09B | $0.09B | +2.1% |
| ▲ Q1 FY2025 | Feb 18, 2025 | $0.04 | $0.70 | +1650.0% | $0.10B | $0.08B | +21.1% |
| ▲ Q4 FY2024 | Oct 29, 2024 | -$0.19 | $0.04 | +121.0% | $0.08B | $0.08B | -4.2% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Miss
EPS Actual
-$0.28
EPS Est.
-$0.06
EPS Surpr.
-366.7%
Revenue
$0.10B
Q1 FY2026
Feb 23, 2026Beat
EPS Actual
$0.14
EPS Est.
$0.11
EPS Surpr.
+27.3%
Revenue
$0.12B
Q4 FY2025
Oct 28, 2025Beat
EPS Actual
$0.49
EPS Est.
$0.28
EPS Surpr.
+75.0%
Revenue
$0.12B
Q3 FY2025
Jul 29, 2025Beat
EPS Actual
$0.50
EPS Est.
$0.10
EPS Surpr.
+400.0%
Revenue
$0.10B
Q2 FY2025
Apr 30, 2025Beat
EPS Actual
$0.28
EPS Est.
$0.11
EPS Surpr.
+154.6%
Revenue
$0.09B
Q1 FY2025
Feb 18, 2025Beat
EPS Actual
$0.70
EPS Est.
$0.04
EPS Surpr.
+1650.0%
Revenue
$0.10B
Q4 FY2024
Oct 29, 2024Beat
EPS Actual
$0.04
EPS Est.
-$0.19
EPS Surpr.
+121.0%
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.34 | $0.34 | $0.35 | 3 |
| Q3 FY2028 | $0.20 | $0.20 | $0.20 | 2 |
| Q2 FY2028 | $0.08 | $0.09 | $0.09 | 2 |
| Q1 FY2028 | $0.06 | $0.06 | $0.06 | 3 |
| Q4 FY2027 | $0.41 | $0.41 | $0.42 | 2 |
| Q3 FY2027 | $0.32 | $0.32 | $0.33 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q1 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 4, 2026 | -366.7% | $65.38 | $67.93 | +3.90% |
| ▲ Q1 FY2026 | Feb 23, 2026 | +27.3% | $82.06 | $87.08 | +6.12% |
| ▲ Q4 FY2025 | Oct 28, 2025 | +75.0% | $130.66 | $137.47 | +5.21% |
| ▲ Q3 FY2025 | Jul 29, 2025 | +400.0% | $84.91 | $91.78 | +8.09% |
| ▲ Q2 FY2025 | Apr 30, 2025 | +154.6% | $116.97 | $66.85 | -42.85% |
| ▲ Q1 FY2025 | Feb 18, 2025 | +1650.0% | $76.35 | $112.76 | +47.69% |
| ▲ Q4 FY2024 | Oct 29, 2024 | +121.0% | $56.06 | $84.02 | +49.88% |
| ▲ Q3 FY2024 | Jul 30, 2024 | +57.7% | $33.69 | $30.13 | -10.57% |
Q2 FY2026+3.90%
Report Date
May 4, 2026
EPS Beat/Miss
-366.7%
Price Before
$65.38
Price After
$67.93
Q1 FY2026+6.12%
Report Date
Feb 23, 2026
EPS Beat/Miss
+27.3%
Price Before
$82.06
Price After
$87.08
Q4 FY2025+5.21%
Report Date
Oct 28, 2025
EPS Beat/Miss
+75.0%
Price Before
$130.66
Price After
$137.47
Q3 FY2025+8.09%
Report Date
Jul 29, 2025
EPS Beat/Miss
+400.0%
Price Before
$84.91
Price After
$91.78
Q2 FY2025-42.85%
Report Date
Apr 30, 2025
EPS Beat/Miss
+154.6%
Price Before
$116.97
Price After
$66.85
Q1 FY2025+47.69%
Report Date
Feb 18, 2025
EPS Beat/Miss
+1650.0%
Price Before
$76.35
Price After
$112.76
Q4 FY2024+49.88%
Report Date
Oct 29, 2024
EPS Beat/Miss
+121.0%
Price Before
$56.06
Price After
$84.02
Q3 FY2024-10.57%
Report Date
Jul 30, 2024
EPS Beat/Miss
+57.7%
Price Before
$33.69
Price After
$30.13
Avg Beat Reaction+9.08%
Avg Miss Reaction+3.90%
Beat Rate7 / 8 quarters
Largest Move+49.88% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: WGS ends December
GeneDx Holdings Corp. (WGS) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $-0.28 — missing the analyst consensus of $-0.06 by -366.7%. The next WGS earnings date is expected around September 1, 2026.
Each quarter, investors track WGS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. WGS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
WGS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
WGS earnings · 5 questionsGeneDx Holdings Corp.'s next earnings report is expected around September 1, 2026. WGS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; WGS historically reports after market close (AMC).
WGS earnings datewhen is WGS earningsWGS next earnings datewhen does WGS report earningsWGS earnings calendar
▸ Source: FMP · GeneDx Holdings Corp. SEC filings · US GAAP · GeneDx Holdings Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026